2.2. Evaluation of CIPN
CIPN, Cancer
PERIPHERAL NEUROPATHY, CANCER
Eligible patients were assessed for early and persistent CIPN using a questionnaire survey for Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-NTX) score at treatment completion (evaluated as early CIPN) and more than 1 year after treatment completion (evaluated as persistent CIPN). Briefly, FACT-NTX has 11 items assessing CIPN-related symptoms with a total score range from 0 to 44. A lower FACT-NTX score indicates worse peripheral neuropathy.